Atomoxetine for Treating ADHD Symptoms in Autism: A Systematic Review

Journal of Attention Disorders

Volumn 17, Issue 8, 2013, Pages 635-640

  Ghanizadeh, Ahmad ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ADHD; atomoxetine; autism; treatment

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ATOMOXETINE; PROPYLAMINE;

ADOLESCENT; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; COMORBIDITY; HUMAN; PRESCHOOL CHILD; REVIEW; TREATMENT;

ADHD; ATOMOXETINE; AUTISM; TREATMENT;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; COMORBIDITY; HUMANS; PROPYLAMINES;

EID: 84885210341     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054712443154     Document Type: Review

References (36)

1. Academy of Medicine Singapore-Ministry of Health clinical practice guidelines: Autism Spectrum Disorders in pre-school children.Singapore Medical Journal. 2010;51:255-263.
2. Adler L. A.,Liebowitz M.,Kronenberger W.,Qiao M.,Rubin R.,Hollandbeck M., Durell T.Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.Depression and Anxiety. 2009;26:212-221.
3. Aman M. G.Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Seminars in Pediatric Neurology; 2004; 2004. 225.
4. Aman M. G.,Farmer C. A.,Hollway J.,Arnold L. E.Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.Child & Adolescent Psychiatrc Clinics of North America. 2008;17:713-738.
5. Arnold L. E.,Aman M. G.,Cook A. M.,Witwer A. N.,Hall K. L.,Thompson S.,Ramadan.Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial.Journal American Academy of Child and Adolescent Psychiatry. 2006;45:1196-1205.
6. Bangs M. E.,Emslie G. J.,Spencer T. J.,Ramsey J. L.,Carlson C.,Bartky E. J., Sumner C. R.Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.Journal of Child and Adolescent Psychopharmacology. 2007;17:407-420.
7. Bangs M. E.,Tauscher-Wisniewski S.,Polzer J.,Zhang S.,Acharya N.,Desaiah D., Allen A. J.Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.Journal of American Academy of Child and Adolescent Psychiatry. 2008;47:209-218.
8. Bymaster F. P.,Katner J. S.,Nelson D. L.,Hemrick-Luecke S. K.,Threlkeld P. G.,Heiligenstein J. H., Perry K. W.Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder.Neuropsychopharmacology. 2002;27:699-711.
9. Charnsil C.Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: An open-label study.Journal of Attention Disorders. 2011;15 (8): 684-689.
10. Cheng J. Y.,Chen R. Y.,Ko J. S.,Ng E. M.Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-Meta-analysis and meta-regression analysis.Psychopharmacology (Berl). 2007;194:197-209.
11. Findling R. L.Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review.Clinical Therapeutic. 2008;30:942-957.
12. Gadow K. D.,DeVincent C. J.,Pomeroy J.ADHD symptom subtypes in children with pervasive developmental disorder.Journal of Autism and Developmental Disorders. 2006;36:271-283.
13. Garnock-Jones K. P.,Keating G. M.Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents.Paediatric Drugs. 2009;11:203-226.
14. Ghanizadeh A.Factor analysis on ADHD and autism spectrum disorder DSM-IV-derived items shows lack of overlap.European Child & Adolescent Psychiatry. 2010;19:797-798.
15. Ghanizadeh A.Co-morbidity and factor analysis on attention deficit hyperactivity disorder and autism spectrum disorder DSM-IV-derived items.Journal of Research in Medical Sciences. 2012;:.
16. Ghanizadeh A.,Mosallaei S.Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome.Brain & Development. 2009;31:15-19.
17. Hazell P.Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder.Journal of Paediatrics and Child Health. 2007;43:19-24.
18. Jou R. J.,Handen B. L.,Hardan A. Y.Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders.Journal of Child and Adolescent Psychopharmacology. 2005;15:325-330.
19. Koda K.,Ago Y.,Cong Y.,Kita Y.,Takuma K.,Matsuda T.Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice.Journal of Neurochemistry. 2010;114:259-270.
20. Kratochvil C. J.,Milton D. R.,Vaughan B. S.,Greenhill L. L.Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy.Child & Adolescent Psychiatry & Mental Health. 2008;2 (1): 25.
21. Liberati A.,Altman D. G.,Tetzlaff J.,Mulrow C.,Gotzsche P. C.,Ioannidis J. P., Moher D.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration.PLoS Medicine. 2009;6 (7): e1000100.
22. McCarthy J.Children with autism spectrum disorders and intellectual disability.Current Opinion in Psychiatry. 2007;20:472-476.
23. Murray M. J.Attention-deficit/hyperactivity disorder in the context of autism spectrum disorders.Current Psychiatry Reports. 2010;12:382-388.
24. Myers S. M.The status of pharmacotherapy for autism spectrum disorders.Expert Opin Pharmacother. 2007;8:1579-1603.
25. Niederhofer H.,Damodharan S. K.,Joji R.,Corfield A.Atomoxetine treating patients with autistic disorder.Autism. 2006;10:647-649.
26. Perwien A. R.,Faries D. E.,Kratochvil C. J.,Sumner C. R.,Kelsey D. K.,Allen A. J.Improvement in health-related quality of life in children with ADHD: An analysis of placebo controlled studies of atomoxetine.Journal of Developmental & Behavioral Pediatrics. 2004;25:264-271.
27. Polanczyk G.,Bigarella M. P.,Hutz M. H.,Rohde L. A.Pharmacogenetic approach for a better drug treatment in children.Current Pharmaceutical Design. 2010;16:2462-2473.
28. Posey D. J.,Aman M. G.,McCracken J. T.,Scahill L.,Tierney E.,Arnold L. E., McDougle C. J.Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures.Biological Psychiatry. 2007;61:538-544.
29. Posey D. J.,Wiegand R. E.,Wilkerson J.,Maynard M.,Stigler K. A.,McDougle C. J.Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.Journal of Child and Adolescent Psychopharmacology. 2006;16:599-610.
30. Rajapakse T.,Pringsheim T.Pharmacotherapeutics of Tourette syndrome and stereotypies in autism. Seminars in Pediatric Neurology; 2010; 2010. 254.
31. Sangal R. B.,Owens J.,Allen A. J.,Sutton V.,Schuh K.,Kelsey D.Effects of atomoxetine and methylphenidate on sleep in children with ADHD.Sleep. 2006;29:1573-1585.
32. Spencer T. J.,Sallee F. R.,Gilbert D. L.,Dunn D. W.,McCracken J. T.,Coffey B. J., Mintz M.Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.Journal of Attention Disorders. 2008;11:470-481.
33. Stigler K. A.,Desmond L. A.,Posey D. J.,Wiegand R. E.,McDougle C. J.A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.Journal of Child and Adolescent Psychopharmacology. 2004;14:49-56.
34. Troost P. W.,Steenhuis M. P.,Tuynman-Qua H. G.,Kalverdijk L. J.,Buitelaar J. K.,Minderaa R. B.,Hoekstra P. J.Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study.Journal of Child and Adolescent Psychopharmacology. 2006;16:611-619.
35. Valicenti-McDermott M.,McVicar K.,Rapin I.,Wershil B. K.,Cohen H.,Shinnar S.Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease.Journal of Developmental & Behavioral Pediatrics. 2006;27:S128-S136.
36. Zeiner P.,Gjevik E.,Weidle B.Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.Acta Paediatrica. 2011;100:1258-1261.